Announcements Trials

Browse Landscape

Status

Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Radiation Injuries 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Cholangiocarcinoma 1 Cervical Cancer Susceptible Population Classification 1 Biliary Tract Neoplasms 1

Interventions

pembrolizumab 55 Carboplatin 33 Paclitaxel 24 Cyclophosphamide 23 Capecitabine 18 sacituzumab govitecan 16 130-nm albumin-bound paclitaxel 15 Specimen Handling 14 toripalimab 11 Drug Therapy 11 Magnetic Resonance Spectroscopy 10 Biopsy 10 Bevacizumab 10 Taxes 9 Epirubicin 9 durvalumab 8 Albumin-Bound Paclitaxel 8 olaparib 7 camrelizumab 7 Gemcitabine 7 Doxorubicin 7 Docetaxel 7 fludarabine 6 famitinib 5 Nivolumab 5 Injections 5 atezolizumab 4 abemaciclib 4 Trastuzumab 4 Standard of Care 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Triple Negative Breast Neoplasms × Base Sequence × Clear all

NCT05916755 2023-06-23

PORTRAIT

Vall d'Hebron Institute of Oncology

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡